On March 31, 2008, pharmaceutical giant AstraZeneca trumpeted the early closing of its so-called JUIPITER trial of a cholesterol-lowering drug (statin), Crestor. The results after only two years yielded “unequivocal evidence” of the drug’s effectiveness, the trial concluded, and the company argued that it could not be withheld from anyone who was well and had normal cholesterol levels but had an elevation in another normal blood constituent, the C-reactive protein (CRP). But, what’s the “other side” of this story?

More Information:

Whew! This is long title describing the remarkable results of a study, just announced at the American Heart Association’s meeting in New Orleans, which showed that AstraZeneca’s cholesterol fighting Crestor (rosuvastatin) slashed deaths, heart attacks, strokes, and artery-clearing procedures in apparently healthy patients who had normal cholesterol levels. The study has made a dramatic impression on some doctors who now expect an adjustment to preventive care guidelines.

More Information: